Targeting Genetic Drivers of Rare Genitourinary Cancers

Video

This video reviews new studies examining the genetic drivers of three rare genitourinary cancers: von Hippel-Lindau disease, advanced papillary renal cell carcinoma, and penile cancer.

In this video, Guru Sonpavde, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, reviews three new studies involving rare genitourinary cancers: a phase II study of pazopanib in von Hippel-Lindau disease (abstract 4516), a comprehensive genomic profiling of advanced papillary renal cell carcinoma (abstract 4517), and a multiregion sequencing of penile cancer that revealed actionable mutations (abstract 4519).

Sonpavde was the discussant during a poster discussion session on the identification and targeting of genetic drivers of rare genitourinary cancers, which featured these three studies, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content